☆ 4.6 Article

Maintenance Treatment for Metastatic Pancreatic Cancer: Balancing Therapeutic Intensity with Tolerable Toxicity

CANCERS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Cancer statistics, 2022

Rebecca L. Siegel et al.

Summary: Each year, the American Cancer Society compiles data on cancer occurrence and outcomes in the United States. The latest data shows that breast and prostate cancer progress has stagnated, while lung cancer has shown improvements in survival rates. Lung cancer incidence for advanced disease has declined while localized-stage rates have increased, resulting in higher survival rates. Mortality patterns align with incidence trends, with lung cancer deaths declining rapidly, breast cancer deaths slowing, and prostate cancer deaths stabilizing.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

添加到收藏夹

Meeting Abstract Oncology

Can stereotactic ablative radiotherapy for oligometastatic pancreatic cancer help avoid perpetual chemotherapy and improve outcomes?

Ahmed Elamir et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Sequential nab-paclitaxel/gemcitabine followed by modified FOLFOX for first-line metastatic pancreatic cancer: The SEQUENCE trial.

Alfredo Carrato et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer

Hedy L. Kindler et al.

Summary: The POLO study demonstrated that active olaparib maintenance therapy did not show a statistically significant overall survival benefit for patients with metastatic pancreatic adenocarcinoma, but did show significant benefits in other secondary endpoints.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Correction Oncology

Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial (vol 23, pg 1009, 2022)

K. A. Reiss et al.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial

Kim A. Reiss et al.

Summary: This study examined the safety and efficacy of maintenance therapy with PARP inhibition combined with immune checkpoint blockade in patients with advanced pancreatic cancer who responded well to platinum-based chemotherapy. The results demonstrated that the combination of niraparib plus ipilimumab was superior to niraparib plus nivolumab in terms of progression-free survival at 6 months.

LANCET ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review

Joanne Lundy et al.

JCO PRECISION ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Docetaxel maintenance therapy versus best supportive care after first-line chemotherapy with different dose docetaxel plus cisplatin for advanced non-small cell lung cancer (TFINE study, CTONG-0904): an open-label, randomized, phase III trial

Li Zhang et al.

Summary: The TFINE study confirmed the efficacy and safety of docetaxel continuation maintenance therapy in patients with advanced non-small cell lung cancer, with the dose of 60 mg/m(2) being potentially preferred by patients. Both docetaxel doses showed comparable toxicities.

ANNALS OF TRANSLATIONAL MEDICINE (2021)

添加到收藏夹

Article Immunology

PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer

Yali Wang et al.

Summary: This study demonstrates that PARP inhibitors can increase PD-L1 expression in pancreatic cancer cells, and when used in combination with PD-L1 blockers, the therapeutic efficacy is significantly improved along with an increase in CD8(+) T cell density. Therefore, the combination therapy of PARP inhibitors with anti-PD-L1/PD-1 drugs may hold potential clinical significance for the treatment of pancreatic cancer.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma

Talia Golan et al.

Summary: By analyzing whole genome sequencing data of PDAC patients, HRD-PDAC can be better identified, and patients without BRCA/PALB2 mutations may also benefit from DNA damage response agents.

GASTROENTEROLOGY (2021)

添加到收藏夹

Article Oncology

Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2

Kim A. Reiss et al.

Summary: This study assessed the role of the PARPi rucaparib as maintenance therapy in advanced pancreatic cancer patients with germline or somatic pathogenic variants in BRCA1, BRCA2, or PALB2, and found it to be a safe and effective treatment option, showing efficacy in a subset of patients.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic Cancer

Na Li et al.

Summary: The study found that olaparib was more cost-effective than placebo for maintenance therapy in metastatic pancreatic cancer in both China and the United States.

FRONTIERS IN PHARMACOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Estimated Projection of US Cancer Incidence and Death to 2040

Lola Rahib et al.

Summary: This cross-sectional study projected cancer incidences and deaths in the United States up to 2040. The findings indicate significant changes in the most common cancers by 2040, with breast cancer projected to become the most common cancer and lung cancer remaining the leading cause of cancer-related death.

JAMA NETWORK OPEN (2021)

添加到收藏夹

Review Oncology

Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis

Raffaella Casolino et al.

Summary: The study analyzed the prevalence of HRD in PDAC patients, finding that surrogate markers of HRD identified more patients than gene-level approaches. There is a need to harmonize HRD definitions and validate the optimal biomarker for treatment selection. Universal HRD screening, including integrated somatic and germline analysis, should be offered to all PDAC patients.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial

Laetitia Dahan et al.

Summary: This study found that maintenance treatment with leucovorin plus fluorouracil is feasible and effective in patients with mPC controlled after 4 months of induction chemotherapy with FOLFIRINOX. However, there was a higher incidence of severe neurotoxicity in the maintenance therapy arm.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Clinical Effects of Stereotactic Body Radiation Therapy Targeting the Primary Tumor of Liver-Only Oligometastatic Pancreatic Cancer

Xiaoqin Ji et al.

Summary: The addition of SBRT to chemotherapy has shown to improve overall survival in liver-only oligometastatic pancreatic cancer patients, especially those with primary tumor located in the head of pancreas or good performance status. Moreover, SBRT is a safe and effective method for local progression control and local symptomatic relief in patients with metastatic pancreatic cancer.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Gemcitabine plus nab-paclitaxel followed by maintenance treatment with gemcitabine alone as first-line treatment for older adults with locally advanced or metastatic pancreatic cancer

Roberto Petrioli et al.

JOURNAL OF GERIATRIC ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation

Max M. Wattenberg et al.

BRITISH JOURNAL OF CANCER (2020)

添加到收藏夹

Article Oncology

Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation

Eileen M. O'Reilly et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article

An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocarcinoma

Katherine M. Bever et al.

Oncotarget (2020)

添加到收藏夹

Article Oncology

FOLFIRINOX De-Escalationin Advanced Pancreatic Cancer: A MulticenterReal-LifeStudy

Hortense Chevalier et al.

ONCOLOGIST (2020)

添加到收藏夹

Article Oncology

Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial

Mei Zhan et al.

CANCER MANAGEMENT AND RESEARCH (2020)

添加到收藏夹

Article Genetics & Heredity

Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer

Matthew B. Yurgelun et al.

GENETICS IN MEDICINE (2019)

添加到收藏夹

Article Medicine, General & Internal

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

Talia Golan et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Medicine, General & Internal

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

A. Gonzalez-Martin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Oncology

Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib

P. Hammel et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

I. Ray-Coquard et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Oncology

Maintenance Therapy with FOLFIRI after FOLFIRINOX for Advanced Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Analysis

Caspar Franck et al.

JOURNAL OF ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial

Wen Zhang et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)

添加到收藏夹

Review Oncology

Development of PARP and Immune-Checkpoint Inhibitor Combinations

Ross A. Stewart et al.

CANCER RESEARCH (2018)

添加到收藏夹

Article Oncology

Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma

Koji Shindo et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

添加到收藏夹

Review Multidisciplinary Sciences

PARP inhibitors: Synthetic lethality in the clinic

Christopher J. Lord et al.

SCIENCE (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Feasibility of alternating induction and maintenance chemotherapy in pancreatic cancer

Alexander Hann et al.

SCIENTIFIC REPORTS (2017)

添加到收藏夹

Article Oncology

PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression

Shiping Jiao et al.

CLINICAL CANCER RESEARCH (2017)

添加到收藏夹

Article Medicine, General & Internal

Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib The LAP07 Randomized Clinical Trial

Pascal Hammel et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)

添加到收藏夹

Article Oncology

Effectiveness and Tolerability of Maintenance Capecitabine Administrated to Patients with Metastatic Pancreatic Cancer Treated with First-Line FOLFIRINOX

Juliette Reure et al.

ONCOLOGY (2016)

添加到收藏夹

Article Medicine, General & Internal

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group

Lieke H. J. Simkens et al.

LANCET (2015)

添加到收藏夹

Article Oncology

Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial

Susanna Hegewisch-Becker et al.

LANCET ONCOLOGY (2015)

添加到收藏夹

Article Oncology

CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer

Tomoe Higuchi et al.

CANCER IMMUNOLOGY RESEARCH (2015)

添加到收藏夹

Article Oncology

Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

Lola Rahib et al.

CANCER RESEARCH (2014)

添加到收藏夹

Article Oncology

Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: A phase II randomised trial

Michele Reni et al.

EUROPEAN JOURNAL OF CANCER (2013)

添加到收藏夹

Article Medicine, General & Internal

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Daniel D. Von Hoff et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

添加到收藏夹

Article Oncology

Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non-Small-Cell Lung Cancer

Maurice Perol et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

添加到收藏夹

Article Medicine, General & Internal

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Thierry Conroy et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

添加到收藏夹

Article Medicine, General & Internal

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

Tudor Ciuleanu et al.

LANCET (2009)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.